Measuring the cost and comparative effectiveness of different treatments for localized prostate cancer is difficult. A recent paper by Cooperberg and colleagues has attempted to address this difficulty, but, although some valuable insights are obtained through their skillful work, its applicability is limited.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Cooperberg, M. R. et al. Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis. BJU Int. doi:10.1111/j.1464-410X.2012.11597.x.
Chun, F. K. et al. Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation. BJU Int. 98, 329–334 (2006).
Zelefsky, M. J. et al. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J. Clin. Oncol. 28, 1508–1513 (2010).
Yossepowitch, O. et al. Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur. Urol. 53, 950–959 (2008).
Konski, A. et al. Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 66, 408–415 (2006).
Nguyen, P. L. et al. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J. Clin. Oncol. 29, 1517–1524 (2011).
Hunink, M. G. M. et al. Decision making in health and medicine: integrating evidence and values. 3 (Cambridge University Press, Cambridge, UK, 2001).
Timbie, J. W., Fox, D. S., Van Busum, K. & Schneider, E. C. Five reasons that many comparative effectiveness studies fail to change patient care and clinical practice. Health Aff. (Millwood) 31, 2168–2175 (2012).
Ou, Y. C. et al. The learning curve for reducing complications of robotic-assisted laparoscopic radical prostatectomy by a single surgeon. BJU Int. 108, 420–425 (2011).
Baade, P. D. et al. Factors associated with treatment received by men diagnosed with prostate cancer in Queensland, Australia. BJU Int. doi:10.1111/j.1464-410X.2012.011533.x.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Yu, J. Interpreting cost-utility analysis of prostate cancer treatment. Nat Rev Urol 10, 129–131 (2013). https://doi.org/10.1038/nrurol.2013.17
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2013.17
